MD Anderson Research Highlights for May 8, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments at MD Anderson offer insights into expanding the use of FGFR inhibitors, maintaining...
ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy alone
ABSTRACT: LBA41
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (...
MD Anderson Research Highlights: ESMO 2023 Special Edition
ABSTRACTS: LBA71, 1088MO, 95MO, LBA48, 1082O, 1085O, LBA34, 243MO
The University of Texas MD Anderson Cancer Center’s Research Highlights...
MD Anderson ranked #1 in the nation for cancer care
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report’s 2023-24 “Best Hospitals” survey. The institution has been one of the nation’s top two hospitals for cancer care since the survey’s inception in 1990.
“At MD Anderson, we remain singularly focused on eliminating cancer,” said Peter WT Pisters, M.D., president of MD Anderson. “We are pleased...
MD Anderson Research Highlights for March 29, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for March 8, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson named #1 in the nation for cancer care
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report...
MD Anderson study finds gene mutations sensitize tumors to specific cancer drugs
Commonly mutated tumor suppressor represents a new target for treating certain cancers
MD Anderson News Release 06/11/2015